Rasagiline (Azilate) dosage adjustment method and individualized medication plan

Rasagiline (Rasagiline) is a selective monoamine oxidaseB inhibitor. It is mainly used to treat early stage Parkinson's disease and mid-to-late stage patients treated with levodopa combination therapy. By inhibiting dopamine degradation, rasagiline increases central nervous system dopamine levels, thereby improving motor symptoms of Parkinson's disease. Reasonable dose adjustment and individualized medication are of great significance for improving efficacy and reducing adverse reactions.

The standard dose is 1 mg taken orally once daily, independent of meals. Clinically, some patients may have poor tolerance or comorbid diseases, and the dose needs to be adjusted according to the patient's specific conditions. For example, patients with mild to moderate impairment of liver function can maintain the standard dose, while patients with severe impairment of liver function are generally not recommended. During the course of medication, if the patient experiences adverse reactions or drug interactions, he or she should promptly evaluate whether to adjust the dosage.

Individualized medication plans need to comprehensively consider the patient's age, disease duration, concomitant medications, and past efficacy. For elderly patients or patients with multiple chronic diseases, doctors can appropriately extend the follow-up interval based on tolerance and closely monitor adverse reactions. For patients with early-stage Parkinson's disease, it can be used as a single drug to maintain motor function; for patients with intermediate and advanced stages, it can be used in combination with levodopa, and the overall efficacy can be optimized by adjusting the dose of levodopa.

During clinical follow-up, patients' motor symptoms, quality of life, and laboratory indicators should be regularly evaluated, with special attention to blood pressure changes and mental status. Dose adjustment should be based on the principles of maximizing efficacy and minimizing side effects, and should be dynamically adjusted based on follow-up results. Scientifically formulating individualized medication plans can improve the safety and long-term efficacy of rasagiline treatment, allowing patients to achieve optimal motor function improvement.

Reference materials:https://www.drugs.com/